Suppliers and packagers for alprostadil

alprostadil

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Meitheal	ALPROSTADIL	alprostadil	INJECTABLE;INJECTION	075196	ANDA	Meitheal Pharmaceuticals Inc.	71288-206-02	10 VIAL, SINGLE-USE in 1 CARTON (71288-206-02) / 1 mL in 1 VIAL, SINGLE-USE (71288-206-01)	2024-09-15

ALPROSTADIL SUPPLIERS: INTELLECTUAL PROPERTY LANDSCAPE AND MARKET DYNAMICS

Last updated: February 19, 2026

This analysis details the intellectual property landscape surrounding alprostadil and identifies key suppliers in the pharmaceutical drug market. Patent filings and market data indicate ongoing competition and potential for new market entrants, particularly concerning generic formulations and novel delivery systems.

What is Alprostadil?

Alprostadil, also known as prostaglandin E1 (PGE1), is a naturally occurring prostaglandin with vasodilatory and platelet aggregation inhibitory properties. Its therapeutic applications include the treatment of erectile dysfunction and patent ductus arteriosus in neonates. The drug is administered via intravenous infusion, intraurethral suppositories, or intracavernosal injection.

Global Patent Filings for Alprostadil

The patent landscape for alprostadil reveals a history of innovation and ongoing strategic patenting by both originator and generic manufacturers. Analysis of patent databases highlights trends in formulation development, manufacturing processes, and novel therapeutic indications.

Key Patent Trends:

• Early Formulation Patents: Initial patents focused on the stabilization and formulation of alprostadil for intravenous administration, addressing its inherent instability. These patents have largely expired.
• Delivery System Innovations: Subsequent patent activity has concentrated on improving drug delivery. This includes:
  • Intraurethral suppositories (e.g., MUSE® by Polymedica, now Employed).
  • Novel injectable formulations with extended release profiles.
  • Transdermal delivery systems (less common but explored).
• Manufacturing Process Patents: Patents related to improved synthetic routes or purification methods for alprostadil and its precursors are also present. These can offer competitive advantages in cost and purity.
• Combination Therapies: Some filings explore the use of alprostadil in combination with other active pharmaceutical ingredients for synergistic effects.

Notable Patent Expirations:

The expiry of key patents for the original alprostadil formulations has opened the door for generic competition. This has led to price erosion and increased market accessibility. However, companies continue to file patents on new formulations and delivery methods to extend market exclusivity.

Patent Category	Typical Expiry Year Range	Impact on Market
Original IV Formulations	2005 - 2015	Enabled widespread generic entry for IV infusions.
Intraurethral Suppositories (e.g., MUSE®)	2018 - 2023	Created a protected niche; generic entry ongoing.
Novel Injectable Formulations	2025 - 2035	Potential for new market segmentation and exclusivity.
Manufacturing Process Improvements	Varies	Affects cost of goods and competitive positioning.

Key Suppliers and Manufacturers

The alprostadil market involves a range of manufacturers, from originators of branded products to significant players in the generic API and finished dosage form markets. Competition exists across various geographical regions, with a notable presence in North America, Europe, and Asia.

Primary Alprostadil API Suppliers:

These companies produce the active pharmaceutical ingredient alprostadil. Their manufacturing capabilities, regulatory compliance (e.g., GMP certification), and pricing are critical factors for finished dosage form manufacturers.

• Teva Pharmaceutical Industries Ltd.: A major global pharmaceutical company with a significant API manufacturing footprint. Teva is known to produce various APIs, including those for cardiovascular and hormonal therapies.
• Hikma Pharmaceuticals PLC: A multinational pharmaceutical group focused on developing, manufacturing, and marketing a broad range of generic and branded products. Hikma has a strong presence in injectables and APIs.
• Fresenius Kabi AG: A subsidiary of Fresenius SE & Co. KGaA, specializing in life-saving medicines and technologies for infusion, transfusion, and clinical nutrition. They are a significant producer of injectable APIs and finished products.
• Fresenius Medical Care AG & Co. KGaA: While primarily known for dialysis products, Fresenius has diversified into other pharmaceutical areas, including APIs.
• Viatris Inc.: Formed by the merger of Pfizer's Upjohn and Mylan, Viatris is a large generics and specialty pharmaceutical company with extensive API manufacturing capabilities.
• Sun Pharmaceutical Industries Ltd.: India-based Sun Pharma is one of the largest generic pharmaceutical companies globally, with broad API and finished dosage form manufacturing.
• Dr. Reddy's Laboratories Ltd.: Another prominent Indian pharmaceutical company with a strong API business and a global presence in generics.
• Piramal Pharma Solutions: While primarily a CDMO, Piramal has significant API manufacturing capabilities that could include alprostadil for specific clients.

Finished Dosage Form Manufacturers (Branded and Generic):

These companies formulate and market alprostadil as finished drug products.

• Mylan N.V. (now part of Viatris Inc.): Historically a major supplier of generic alprostadil injectables.
• Sandoz International GmbH (part of Novartis AG): A leading global generic pharmaceutical company with a broad portfolio, including injectables.
• Fresenius Kabi AG: Offers alprostadil as an intravenous infusion product.
• Bausch Health Companies Inc.: While known for other therapeutic areas, Bausch Health has a diverse product portfolio that may include alprostadil-containing products or previously held rights.
• Amneal Pharmaceuticals LLC: A growing generics company with manufacturing capabilities for injectables and other dosage forms.
• Cosette Pharmaceuticals, Inc.: A specialty pharmaceutical company focused on acquiring and developing generic and differentiated products, including injectables.
• Bristol-Myers Squibb Company: While the originator of some early alprostadil products, their current direct involvement in the generic API or finished product market for alprostadil is less prominent compared to dedicated generics players.

Note: Supplier lists are dynamic and can change due to mergers, acquisitions, and strategic shifts. Companies may also act as both API suppliers and finished dosage form manufacturers.

Market Dynamics and Competitive Landscape

The alprostadil market is characterized by a mature segment for intravenous formulations driven by generic competition and a more specialized segment for intraurethral delivery systems with ongoing patent protection and limited generic penetration.

Key Market Drivers:

• Aging Population: Increases the prevalence of conditions like erectile dysfunction, driving demand for treatments.
• Neonatal Care Advancements: Continued need for alprostadil in treating congenital heart defects in newborns.
• Generic Accessibility: Expiration of primary patents has made alprostadil more affordable, expanding its use.
• Emerging Markets: Growing healthcare infrastructure and access in developing economies contribute to demand.

Competitive Pressures:

• Price Erosion: Intense competition among generic manufacturers for IV formulations significantly impacts pricing.
• Regulatory Hurdles: Obtaining and maintaining GMP certification and navigating complex regulatory approval processes in different regions are critical barriers to entry.
• Supply Chain Security: Ensuring a consistent and high-quality supply of alprostadil API is paramount for finished dosage form manufacturers. Geopolitical factors and manufacturing disruptions can pose risks.
• Innovation in Delivery: Companies holding patents on novel delivery systems (e.g., improved suppositories, extended-release injections) can command premium pricing and maintain market share.

Intellectual Property as a Differentiator:

Despite the generic nature of some alprostadil products, intellectual property remains a critical differentiator.

• Process Patents: Continuous improvement in manufacturing processes can lead to cost advantages or higher purity APIs, providing a competitive edge.
• Formulation Patents: Novel formulations that improve stability, patient compliance, or efficacy (e.g., reduced side effects) can create new market opportunities and extend product lifecycles.
• Combination Products: Patents on alprostadil combined with other agents for specific indications represent a frontier for innovation and market exclusivity.

Key Takeaways

The alprostadil market is mature for intravenous formulations, driven by robust generic competition and price pressures. However, innovation in drug delivery systems, particularly for intraurethral and injectable applications, continues to be an area of significant intellectual property activity and potential market differentiation. Key API suppliers are predominantly large, global pharmaceutical companies with strong regulatory compliance. Finished dosage form manufacturers face intense competition, with success often hinging on cost efficiency for generics and the strategic leverage of remaining patent protection for differentiated products.

Frequently Asked Questions

What is the patent status of alprostadil for erectile dysfunction?

Patents covering the original alprostadil formulations for erectile dysfunction, especially intravenous and early intraurethral methods, have largely expired, leading to widespread generic availability. However, patents for newer delivery systems, such as improved intraurethral formulations or specific injectable compositions with enhanced stability or release profiles, may still be in force.

Which companies are the largest manufacturers of alprostadil API?

Major global pharmaceutical companies with extensive API manufacturing capabilities, including Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Fresenius Kabi AG, Viatris Inc., Sun Pharmaceutical Industries Ltd., and Dr. Reddy's Laboratories Ltd., are significant suppliers of alprostadil API.

How do patent expirations impact the alprostadil market?

Patent expirations, particularly for widely used formulations like intravenous alprostadil, lead to increased generic competition. This typically results in significant price reductions for the drug and expanded market access. However, originators may seek to maintain market share through newer, patented delivery systems or formulations.

Are there new therapeutic applications for alprostadil being patented?

While alprostadil's primary indications are established, patent filings may explore its use in combination therapies or for less common vascular or oncological applications. Research into novel delivery methods could also indirectly lead to patents that support existing or new therapeutic uses by improving drug performance.

What are the main challenges for new entrants in the alprostadil market?

New entrants face significant challenges, including the need to establish GMP-compliant manufacturing for API or finished dosage forms, navigate complex regulatory approval pathways in multiple jurisdictions, secure a reliable supply chain, and compete against established generic players with economies of scale and lower cost structures. Intellectual property held by existing manufacturers for novel formulations or processes also presents a barrier.

Citations

[1] U.S. Food & Drug Administration. (n.d.). Drugs@FDA. Retrieved from https://www.accessdata.fda.gov/scripts/cder/daf/ [2] European Patent Office. (n.d.). Espacenet. Retrieved from https://worldwide.espacenet.com/ [3] World Intellectual Property Organization. (n.d.). PATENTSCOPE. Retrieved from https://patentscope.wipo.int/ [4] Company Investor Relations Websites (Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Fresenius Kabi AG, Viatris Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd.). (Various Dates). Annual Reports and SEC Filings. [5] Pharmaceutical Industry Market Research Reports (Various Publishers). (Ongoing). Global Pharmaceutical Market Analysis.